ZME Science on MSN2h
Could CAR-T Therapy Be the End of Lifelong Lupus Medication? Early Results Say ‘Yes’T-cells are real life saviors. If modified properly, they can save lupus patients from the trouble of taking medicines ...
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...
Autolus Therapeutics has secured US Food and Drug Administration (FDA) approval for Aucatzyl (obecaktagene autoleucel), its ...
Most cancer treatments—from chemotherapies to engineered immune cells—have a host of side effects, in large part because they ...
Engineered receptors could lead to more precisely targeted, effective cancer therapies with fewer side effects than existing ...
INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim ...
Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on CARGO Therapeutics, Inc. (CRGX – Research Report) today and set a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback